Gujarat Themis Biosyn Ltd. (BSE: 506879) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,843 Cr, it ranks #851 by market cap among the 6,137 Indian listed companies on FinBizNet, and #27 of 86 in Medicinal Chemicals and Botanical Products. At ₹324.00 (as of 25 Oct 2026), the share price is 32.4% below its 52-week high of ₹479.00 and 44.0% above its 52-week low of ₹225.05. The share price is down 24.7% over one year and down 10.1% over three months.
| Current Price | ₹324.00 |
|---|---|
| Market Cap | ₹4,843 Cr |
| BSE Code | 506879 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 84 |
| Return on Equity | 17.41% |
| Return on Assets | 9.74% |
| 52-Week Range | ₹225.05 – ₹479.00 |
| 1-Year Price Change | -24.7% |
| 3-Month Price Change | -10.1% |
| Beta (1Y) | 0.78 |
| Dividend Yield | 0.19% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.gtbl.in |
| Revenue | ₹44 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 25.3% |
| EPS (Basic) | ₹1.02 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.
1. Manufacturing Bulk Drugs-This segment manufactures bulk drugs.
1. Manufacturing Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Gujarat Themis Biosyn Ltd. | ₹4,843 Cr | 84 | 17.41% | ₹44 Cr | -24.7% |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Themis Biosyn Ltd. is trading at ₹324.00, with a market capitalisation of ₹4,843 Cr.
Gujarat Themis Biosyn Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Gujarat Themis Biosyn Ltd. has a P/E of 84 and a return on equity of 17.41%.
Gujarat Themis Biosyn Ltd. is listed on the BSE under the scrip code 506879.
Gujarat Themis Biosyn Ltd.'s share price is down 24.7% over one year and down 10.1% over three months. Its 52-week range is ₹225.05 to ₹479.00.
In Q1 FY27, Gujarat Themis Biosyn Ltd. reported revenue of ₹44 Cr and net profit of ₹11 Cr, with basic EPS of ₹1.02 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.